42 results about "White adipose tissue" patented technology

Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

The present invention provides nanoparticles or compositions thereof comprising resveratrol and / or quercetin, or derivatives, prodrugs, or pharmaceutically acceptable salts thereof, at least one lipid, at least one surfactant, and at least one vitamin E. In some embodiments, the nanoparticles or compositions thereof further comprise at least one targeting agent. In some embodiments, the nanoparticles or compositions thereof are targeted for an adipose tissue of interest. In some aspects, the present invention provides methods of activating brown adipose tissue or browning white adipose tissue or beige adipose tissue of interest. In some aspects, the present invention provides methods of reducing body fat, inducing weight loss, and / or improving glucose homeostasis and insulin sensitivity. In some aspects, the present invention provides methods of optimizing the composition of the gut microbiota. In some aspects, the present invention provides methods of treating or preventing various diseases or disorders, such as obesity.

The present invention relates to a novel plant lactobacillus strain and a composition for preventing or treating metabolic diseases comprising the strain. According to the plant lactobacillus strain (preservation number KCTC 14107BP) of the present invention, fat accumulation in white adipose tissue, brown adipose tissue and liver tissue can be effectively inhibited. The plant lactobacillus strain shows an excellent blood sugar improvement effect, particularly can reduce fasting blood sugar level. The plant lactobacillus strain can improve glucose tolerance and increase insulin sensitivity, thereby effectively improving insulin resistance. In addition, the plant lactobacillus strain can control the concentration of metabolic hormones in the blood. Therefore, the plant lactobacillus strain can be usefully used to prevent or treat metabolic diseases.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

Provided is a polynucleotide including a nucleotide sequence encoding a vestigial like 4 protein and a cis-regulatory element that controls hepatocyte-specific expression of the sequence encoding a vestigial like 4 protein. Also provided is a viral vector including the polynucleotide, and a cell or organism transfected by the polynucleotide. Also provided is a method of treating steatohepatitis, obesity, hyperglycemia, diabetes, insulin resistance, liver inflammation, or decreasing white adipose tissue in the subject. Also provided is a method of screening a treatment for fatty liver disease or prevention of cirrhosis, comprising feeding a diet high in fat, fructose, and / or cholesterol to a transgenic animal having an hepatocyte-specific vestigial like protein gene disruption, administering the treatment to the transgenic animal, and detecting a difference in liver morphology or liver function between the transgenic animal and a control animal.

The present invention discloses a strain of malic acid-enriched strictly anaerobic Faecalibacterium rodentium RFM0224 for preventing obesity and its application, belonging to the technical field of intestinal microorganism-host interaction and its application. The present invention isolates a strain of Faecalibacterium rodentium RFM0224 for the first time, which is a Gram-positive bacterium and an endogenous strain in the intestine of mammals. It can reduce the accumulation of white adipose tissue in the body under a high-fat diet, reduce the levels of total cholesterol (TC) and triglycerides (TG) in serum, and can significantly downregulate the expression of colon inflammatory cytokines IL-6, IL-1β and TNF-αmRNA. This lays a foundation for the use of this strain and the bacterial agent developed based on this strain in the preparation of products related to the prevention and treatment of intestinal inflammation, obesity and hyperlipidemia.

The invention relates to the technical field of novel application of targeted drugs, in particular to application of Plitidepsin in preparation of drugs for treating obesity and improving glucose metabolism. It can be known through exploration that plitidepsin can reduce the weight and fat content of a treated object and the content of white adipose tissue around inguinal white fat and epididymis, and meanwhile, the sugar tolerance and insulin sensitivity of the treated object can be improved. Therefore, the plitidepsin can be used for preparing the medicine for treating obesity and improving glucose metabolism.

The invention relates to the technical field of obesity inhibition, in particular to a composition for inhibiting obesity and a preparation method and application thereof. According to the invention, the red pimento extract, the suberect spatholobus stem extract and the chlamydomonas reinhardtii are combined, and the red pimento extract rich in capsaicin ester promotes body lipid oxidative metabolism, activates brown adipose tissues, promotes white adipose tissue browning and increases energy consumption by increasing body lipid metabolism heat production; meanwhile, the suberect spatholobus stem extract containing isoflavone compounds is used for maintaining the steady state of glucose and reducing insulin resistance to up-regulate metabolic regulators, chlamydomonas reinhardtii is compounded, the chlamydomonas reinhardtii has high protein, low fat, rich dietary fibers and strong satiety, weight control is facilitated, and the suberect spatholobus stem extract, the suberect spatholobus stem extract and the chlamydomonas reinhardtii have a synergistic effect; the traditional Chinese medicine composition can regulate and control metabolites, influence related signal channels, promote white fat browning, and achieve the purposes of obesity inhibition and weight loss.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

The present application relates to the application of delta-Viniferin in the preparation of drugs for preventing or treating metabolic cardiovascular diseases. Delta-Viniferin can inhibit the expression level of aging and inflammation related genes / proteins of vascular endothelial cells, reduce endothelial dysfunction, and clarify its anti-hypertensive effect. Delta-Viniferin can inhibit the expression level of vascular smooth muscle cell phenotype conversion related genes / proteins, improve the contraction function of vascular smooth muscle, and significantly alleviate the degradation of elastic fibers of the vascular wall and the rupture of the intima of the aortic wall in vivo, and clarify its effect on preventing and treating aortic dissection. Delta-Viniferin can inhibit the expression level of myocardial fibroblast fibrosis related genes / proteins, and clarify its anti-myocardial fibrosis effect. Delta-Viniferin can promote white adipose tissue browning by targeting the SIRT1-FOXO1 axis, increase energy consumption, and clarify its effect on resisting obesity. In summary, the compound delta-Viniferin has the effect of protecting various metabolic cardiovascular diseases, and can be used to prepare drugs for preventing and treating metabolic cardiovascular diseases.

Topical compositions and methods are provided that are effective for promoting an optimal composition of dermal white adipose tissue in vivo comprising an adipogenic agent, a retarder of lipogenesis or lipolytic agent and at least one penetrant.

The invention relates to application of extracellular vesicles derived from post-exercise groin white fat in preparation of a medicine for preventing and / or treating myocardial ischemia-reperfusion injury. The extracellular vesicles are derived from autokinetic white adipose tissues of groins, after long-term aerobic exercise (such as swimming or running), the extracellular vesicles in the white adipose tissues of groins are extracted, and it is found that the extracellular vesicles can remarkably reduce the myocardial infarction area caused by acute myocardial ischemia reperfusion, and the myocardial infarction effect is remarkably improved. And cardiac function decline and cardiac fibrosis caused by long-term myocardial ischemia reperfusion are inhibited. Experiments show that the exercised extracellular vesicles can inhibit apoptosis of myocardial cells. The invention provides a new treatment strategy for prevention and treatment of myocardial ischemia reperfusion injury.

The application relates to the technical field of new application of a targeted drug, in particular to application of plitidepsin in preparation of a medicine for treating obesity and improving sugar metabolism. It is known that plitidepsin can reduce the body weight, fat content, and inguinal white adipose tissue and epididymal white adipose tissue content of a treatment object, and can improve the sugar tolerance and insulin sensitivity of the treatment object. Therefore, plitidepsin can be used for preparing a medicine for treating obesity and improving sugar metabolism.

The invention relates to the technical field of biological medicine, in particular to a compound and a preparation method thereof, a photo-thermal agent and application of the photo-thermal agent in obesity treatment. The compound has a structure as shown in a formula I in the specification, wherein R is selected from at least one of anthracene-containing groups, dibenzothiophene-containing groups or carbazole-containing groups, and X is selected from at least one of halogen atoms, PF6 <-> and BF4 <->. The compound provided by the invention has mitochondrial targeting property and good photothermal conversion capability, and can realize obesity treatment by promoting the browning process of white adipose tissues.

The invention discloses a fruit and vegetable fiber capable of improving GLP1 in vivo, which is prepared by the following steps: soaking peels of citrus fruits with hot water, removing white pulp layers, washing with water, and draining; grinding the fruit peels, inoculating aspergillus niger and plant lactobacillus, fermenting and sterilizing to obtain fermented fruit and vegetable fibers; performing ultrasonic treatment, adding water, adding xylanase and cellulase, performing enzymolysis, and performing enzyme deactivation to obtain enzymolysis fruit and vegetable fiber liquid; homogenizing, passing through an ultrafiltration membrane, intercepting filtrate, and spray-drying to obtain insoluble fibers; collecting permeate liquid, passing through a nanofiltration membrane, intercepting filtrate, and freeze-drying to obtain soluble fibers; and compounding the insoluble fiber part and the soluble fiber part to obtain the fruit and vegetable fiber. The invention further discloses application of the fruit and vegetable fibers in sugar control and weight reduction. The traditional Chinese medicine composition can effectively enhance satiety, inhibit excessive accumulation of white adipose tissues, activate a heat production function of brown adipose tissues, regulate body fat balance, activate a GLP-1 signal channel, inhibit appetite center and improve glycolipid metabolism.

The present invention relates to a composition for preventing or treating metabolic dysfunction-associated liver disease comprising oenotein B, wherein oenotein B reduced elevated liver-related parameters in an animal model of metabolic dysfunction-associated steatotic liver disease, reduced body weight, liver weight, and white adipose tissue to alleviate liver steatosis, reduced inflammation, and inhibited liver fibrosis. Therefore, the composition has the effect of being able to be effectively used for preventing or treating metabolic dysfunction-associated liver disease including liver steatosis, metabolic dysfunction steatohepatitis, and liver fibrosis.

The invention discloses an application of rifampicin in preparation of a medicine for regulating lipid metabolism. The invention discloses a new medical application of rifampicin by using a mouse model fed by 3T3-L1 fat cells and high fat diet (HFD). Rifampicin can increase the expression of Sirt6 in vivo and in vitro. In addition, rifampicin effectively blocks differentiation of 3T3-L1 preadipocytes and reduces lipid accumulation by inhibiting lipid generation in adipocytes and enhancing lipid decomposition. In the mechanism level, rifampicin significantly inhibits the expression of adipogenesis genes and proteins, and enhances the expression of genes and proteins of lipolysis, energy consumption and white adipose tissue browning related pathways. In conclusion, data of the invention shows that rifampicin is a potential new treatment strategy for regulating lipid metabolism.

The invention discloses an application of Pantoea ananatis, and relates to the technical field of microorganisms. Aiming at the defects of the existing obesity intervention means, the invention provides a brand-new solution: Pantoea anatitis adapted to a high-altitude environment is used as a core functional strain, through an intestinal flora driving mechanism, the expression of UCP1 protein in brown adipose tissue (BAT) is activated, the heat production function of the BAT is enhanced, and meanwhile, the storage of white adipose tissue (WAT) and the level of liver triglyceride (TG) are reduced; the weight-losing effect is realized. The strain can play a role through an'intestinal flora-BAT 'axis without cold exposure, has no obvious influence on liver functions, and is excellent in safety. The invention discloses a flora-mediated non-cold-dependent BAT activation way for the first time, can be used for preparing products such as weight-reducing medicines and health-care foods, has the advantages of mechanism innovation, exact effect and wide application, and provides a new technical choice for obesity intervention.

To provide topical compositions to promote optimal dermal white adipose tissue formation in vivo, and methods to improve the appearance of skin in an individual.SOLUTION: The present invention provides a topical composition effective for improving the appearance of the skin, comprising at least one adipogenic agent, at least one lipolytic agent and at least one penetrant, wherein the improvement comprises an improvement in the appearance of insufficient volume.SELECTED DRAWING: None

This invention discloses the application of a Dickkopf-related protein 3 regulator in the preparation of metabolic regulation products. This invention is the first to propose and verify the novel functions of exogenous Dickkopf-related protein 3 in the regulation of adipose thermogenesis and the regulation of energy metabolism homeostasis in the body. It clarifies that it can promote lipid decomposition in adipocytes, enhance the thermogenic activity of adipocytes, promote the browning of white adipose tissue, and exert its effects through a non-UCP1-dependent pathway that promotes the stability of SERCA2b protein. This provides a new target and technical means for the intervention of lipid metabolism disorders such as obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease.

The application provides a method for regulating lipid absorption, a composition and application thereof. The present inventors have been committed to the research on the correlation between diet and metabolism, and found in the previous research that compared with before diet restriction, re-feeding after diet restriction can significantly increase the body fat content. Further research shows that the composition of intestinal flora during normal diet after diet restriction changes significantly, and the proportion of lactobacillus increases significantly; high-protein diet after diet restriction can significantly inhibit the increase of the proportion of small intestinal lactobacillus, and the diversity of flora is significantly increased. Clearing the intestinal flora can effectively inhibit the increase of body fat caused by re-feeding after diet restriction. The present inventors have also found that a five-compound combination of a specific lactobacillus strain can significantly increase lipid absorption and fatty acid uptake of white adipose tissue.

The invention discloses bifidobacterium adolescentis and application of the bifidobacterium adolescentis in fat reduction. The bifidobacterium adolescentis is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31381. The bifidobacterium adolescentis has the effects of reducing the body fat rate, reducing weight, inhibiting the body weight rebound after weight loss, maintaining the weight loss effect, improving the blood fat and the like, promotes brown fat to produce heat and promotes white fat to be converted into brown fat, and meanwhile has high safety superior to that of weight-reducing drugs. In addition, when the medicine or food is used for treating and preventing obesity, the total cholesterol and total triglyceride levels are reduced, the liver function is improved, the pancreas health is maintained, the fat cell area is reduced, liver fat infiltration is reduced, the intestinal flora is regulated, and the inflammation level is reduced.

Topical compositions and methods are provided that are effective for promoting an optimal composition of dermal white adipose tissue in vivo comprising an adipogenic agent, a retarder of lipogenesis or lipolytic agent and at least one penetrant.

In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte- specific EVs / adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large- adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.

This invention provides an aptamer targeting the growth hormone receptor and its uses, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. This invention utilizes a modified SELEX technique to perform multiple rounds of screening targeting recombinant GHR protein, obtaining specific nucleic acid aptamers with high affinity for GHR (KD values ​​at the micromolar level). In vivo distribution experiments show that the fluorescently labeled aptamer can efficiently and specifically accumulate in white adipose tissue (including inguinal and gonadal fat) at the in vivo level, exhibiting excellent tissue targeting. The nucleic acid aptamer and its derivatives of this invention can be used to prepare drugs or diagnostic reagents targeting adipose tissue, for example, for the prevention or treatment of metabolic diseases such as obesity, type 2 diabetes, fatty liver, hyperlipidemia, or cardiovascular disease.

This invention discloses a tsRNA molecule associated with the browning of white adipose tissue and its applications. This invention provides a potential therapeutic target for the prevention and / or treatment of obesity and related metabolic diseases.

The invention relates to the technical field of health-care functional food, in particular to novel application of a composition. The composition provided by the invention is prepared from the following raw materials in parts by weight: 120 parts of lotus leaves, 30 parts of haws and 80 parts of mulberry leaves. The raw materials are mainly selected from medicinal and edible food materials and part of common nutritional food materials which are all natural plant raw materials. The applicant deeply studies the characteristics of the raw materials, carries out comprehensive and systematic in-vivo and in-vitro experimental verification respectively by screening and blending various food raw materials according to the two characteristics of preventing and reducing obesity of the product, and finally determines the composition of the optimized variety of the raw materials. The invention also relates to an application of the functional health-care food for preventing and reducing obesity and synchronously protecting intestinal barriers and liver tissues, and the functional health-care food is used for preventing and reducing obesity by inhibiting the whitening of brown fat, promoting the browning of white fat and enhancing the heat energy conversion of body lipid after being taken.

The invention discloses an application of zingerone in preparation of a product for regulating biological lipid metabolism, and finds that zingerone can effectively inhibit weight gain and hyperlipidemia caused by lipid metabolism disorder and effectively reduce the weight increment of white adipose tissues after peritoneum and the adipocyte area for the first time. The liver weight, the liver cell area and the lipid droplet content are obviously reduced, and the liver function is improved. Meanwhile, zingiberone is an effective component extracted from a natural plant ginger, so that zingiberone serving as a lipid metabolism regulating product has relatively good safety. The invention not only provides a new application of zingerone, but also provides a new therapeutic drug or health care product for preventing and treating obesity.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The present invention relates to methods, compositions and kits for treating obesity and / or an obesity-related disease or disorder and / or diabetes in an individual. The present invention also relates to methods, compositions and kits for treating fatty liver disease in an individual. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of obesity, treatment of adiposity, increasing white adipose tissue browning. The invention also provides a method of promoting blood glucose clearance and increased insulin secretion in an overweight or obese individual, the method comprising administering a SIK-3 inhibitor to the individual. The present invention also provides a method of treating fatty liver disease in an individual in need thereof, the method comprising administering to the individual a SIK-3 inhibitor, thereby treating fatty liver disease in the individual in need thereof.